Oncology Support
Advanced IV Therapy for Chemotherapy-Induced Nausea and Vomiting (CINV)
Specialized anti-nausea IV protocol designed for cancer patients undergoing chemotherapy. Combines prescription antiemetics with hydration to manage and prevent CINV effectively.
40-80%
of chemotherapy patients experience CINV without preventive therapy
70-90%
nausea prevention rate with optimized multi-drug IV antiemetic protocols
48-72 hours
duration of delayed CINV typically managed by our IV protocol
Key Capabilities
- •Multi-drug antiemetic approach targeting different nausea pathways (5-HT3, NK1, dopamine receptors)
- •Preventive dosing before and after chemotherapy administration
- •Coordinated with oncology team and chemotherapy schedule
- •Includes dexamethasone for delayed nausea prevention (24-48 hours post-chemo)
- •IV hydration counteracts dehydration from both chemotherapy and antiemetics
- •Preserves nutrition intake and quality of life during cancer treatment
Why It Matters
Enhanced Treatment Tolerance
By preventing or minimizing nausea, patients can better tolerate their chemotherapy regimen, maintain nutritional intake, and avoid missing or delaying critical cancer treatments due to side effect management.
Acute and Delayed CINV Control
Our protocol addresses both acute nausea (within hours of chemo) and delayed nausea (24-72 hours post-treatment) through coordinated timing of antiemetic medications and supportive IV hydration.
Reduced Hospital Admissions
Effective CINV management reduces unplanned emergency room visits and hospitalizations for uncontrolled nausea, vomiting, and dehydration during chemotherapy cycles.
Personalized Oncology Collaboration
Our IV therapy protocols are coordinated with your oncology team, chemotherapy agents used, and individual nausea risk factors to deliver personalized CINV prevention tailored to your specific cancer treatment plan.
Frequently Asked Questions
How does your chemotherapy nausea IV differ from standard anti-nausea medications?
Our protocol uses IV administration of multiple antiemetic classes (5-HT3 antagonists, NK1 antagonists, corticosteroids) for synergistic effect. This multi-modal approach is more effective than single-agent oral medications for chemotherapy-induced nausea, particularly for highly emetogenic chemotherapy regimens.
When should I receive my anti-nausea IV relative to chemotherapy?
Ideally, antiemetic IV therapy begins 30-60 minutes before your chemotherapy infusion to achieve therapeutic drug levels. For delayed CINV prevention, we may schedule additional infusions on days 2-3 post-chemotherapy based on your specific regimen and risk factors.
Can your IV nausea therapy interfere with my chemotherapy?
No. Our antiemetic IV formulations are specifically selected to complement chemotherapy without reducing cancer drug efficacy. We coordinate with your oncology team to ensure all medications work synergistically for optimal cancer treatment and symptom management.
What if I'm already taking oral anti-nausea medication?
IV therapy complements oral antiemetics; we don't simply duplicate them. Our team reviews your current medications and adjusts the IV formulation to avoid redundancy while providing enhanced symptom control through IV administration and synergistic drug combinations.